Goldman Sachs initiates Tempus AI stock coverage with neutral rating

Goldman Sachs began covering Tempus AI Inc (NASDAQ:TEM) on Monday, assigning it a Neutral rating with a price target of $75.00. The current stock price is $77.84, surpassing the target and indicating potential overvaluation according to InvestingPro data. Tempus AI operates two product lines, Diagnostics and Data, which are designed to complement each other, creating synergy for patients and pharma partners.

The Diagnostics segment is expected to benefit from multiple pricing advantages, including an FDA-approved solid tumor xT companion diagnostic assay that will increase reimbursement rates and annualized revenue. Another potential FDA approval, the xF liquid biopsy assay, could further expand revenue by $400 million by 2028. Tempus AI currently boasts a robust 64% gross profit margin on its $1.43 billion revenue base, which has grown by 50% over the past year.

However, the firm identifies risks in the Data and Applications segment, such as high customer concentration and uncertainties around contract renewals and data monetization efforts. Recent analyst evaluations include an upgrade to Overweight by Piper Sandler with a $76 price target, a Buy rating and $66 target from H.C. Wainwright, and an Overweight with an $80 target from Cantor Fitzgerald. These varied perspectives highlight the growing interest and strategic developments in Tempus AI.